Article

Pharmaceutical Executive

Pharmaceutical Executive

Pharmaceutical Executive-05-01-2001
Volume0
Issue 0

Friends of Complexity

Author(s):

Wayne Koberstein

Pharmaceutical executives should study their own scientists. They construct clever tools to explore convoluted phenomena. They are the true friends of complexity.

Articles in this issue
Policy: Task Masters
Pharmacia's Carrie Cox: HBA Woman of the Year
Friends of Complexity
Under Federal Fire
Task Force: Enter the Fixers
The Next Y2K

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Related Content
FDA Grants Accelerated Approval to Boehringer Ingelheim’s Hernexeos for Unresectable or Metastatic Non-Squamous Non-Small Cell Lung Cancer
August 11th 2025

FDA Grants Accelerated Approval to Boehringer Ingelheim’s Hernexeos for Unresectable or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Don Tracy, Associate Editor
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 11th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
He's Back: Vinay Prasad Returns As FDA CBER Head
August 11th 2025

He's Back: Vinay Prasad Returns As FDA CBER Head

PharmExec Staff
Beyond the Prescription: Pharma's Role in Digital Health Conversations
August 11th 2025

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
Stock.adobe.com
August 11th 2025

Radella Pharmaceuticals Release New Obesity Trial Data Showing Significant Weight Loss and Expansive Cardiometabolic Benefits

Nicholas Jacobus
Boehringer Ingelheim, Click Therapeutics’ Investigational Prescription Digital Therapeutic Meets Primary Endpoint in Phase III Study for Schizophrenia Negative Symptoms
August 11th 2025

Boehringer Ingelheim, Click Therapeutics’ Investigational Prescription Digital Therapeutic Meets Primary Endpoint in Phase III Study for Schizophrenia Negative Symptoms

Don Tracy, Associate Editor